Repligen Corp. has entered into an exclusive worldwide licensing agreement with Pfizer to advance its spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).   The SMA program includes RG3039, a small molecule drug candidate in clinical development for SMA, as well as backup compounds and enabling technologies. Repligen is responsible for completing the first two cohorts of an active Phase I trial evaluating RG3039 in healthy volunteers, as well as provide cert...